{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T03:39:18Z","timestamp":1793331558501,"version":"4.5.0"},"reference-count":165,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,12,8]],"date-time":"2020-12-08T00:00:00Z","timestamp":1607385600000},"content-version":"vor","delay-in-days":7,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Epidemiol"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Determine age-specific infection fatality rates for COVID-19 to inform public health policies and communications that help protect vulnerable age groups. Studies of COVID-19 prevalence were collected by conducting an online search of published articles, preprints, and government reports that were publicly disseminated prior to 18 September 2020. The systematic review encompassed 113 studies, of which 27 studies (covering 34 geographical locations) satisfied the inclusion criteria and were included in the meta-analysis. Age-specific IFRs were computed using the prevalence data in conjunction with reported fatalities 4\u00a0weeks after the midpoint date of the study, reflecting typical lags in fatalities and reporting. Meta-regression procedures in Stata were used to analyze the infection fatality rate (IFR) by age. Our analysis finds a exponential relationship between age and IFR for COVID-19. The estimated age-specific IFR is very low for children and younger adults (e.g., 0.002% at age 10 and 0.01% at age 25) but increases progressively to 0.4% at age 55, 1.4% at age 65, 4.6% at age 75, and 15% at age 85. Moreover, our results indicate that about 90% of the variation in population IFR across geographical locations reflects differences in the age composition of the population and the extent to which relatively vulnerable age groups were exposed to the virus. These results indicate that COVID-19 is hazardous not only for the elderly but also for middle-aged adults, for whom the infection fatality rate is two orders of magnitude greater than the annualized risk of a fatal automobile accident and far more dangerous than seasonal influenza. Moreover, the overall IFR for COVID-19 should not be viewed as a fixed parameter but as intrinsically linked to the age-specific pattern of infections. Consequently, public health measures to mitigate infections in older adults could substantially decrease total deaths.<\/jats:p>","DOI":"10.1007\/s10654-020-00698-1","type":"journal-article","created":{"date-parts":[[2020,12,8]],"date-time":"2020-12-08T05:08:04Z","timestamp":1607404084000},"page":"1123-1138","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":668,"title":["Assessing the age specificity of infection fatality rates for COVID-19: systematic review, meta-analysis, and public policy implications"],"prefix":"10.1007","volume":"35","author":[{"given":"Andrew T.","family":"Levin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William P.","family":"Hanage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nana","family":"Owusu-Boaitey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kensington B.","family":"Cochran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seamus P.","family":"Walsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1156-9345","authenticated-orcid":false,"given":"Gideon","family":"Meyerowitz-Katz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,12,8]]},"reference":[{"key":"698_CR1","doi-asserted-by":"publisher","first-page":"e130","DOI":"10.1017\/S0950268820001430","volume":"148","author":"M Khalili","year":"2020","unstructured":"Khalili M, Karamouzian M, Nasiri N, Javadi S, Mirzazadeh A, Sharifi H. Epidemiological characteristics of COVID-19: a systematic review and meta-analysis. Epidemiol Infect. 2020;148:e130. https:\/\/doi.org\/10.1017\/S0950268820001430.","journal-title":"Epidemiol Infect"},{"key":"698_CR2","doi-asserted-by":"publisher","DOI":"10.7326\/M20-3012","author":"DP Oran","year":"2020","unstructured":"Oran DP, Topol EJ. Prevalence of asymptomatic SARS-CoV-2 infection: a narrative review. Ann Intern Med. 2020. https:\/\/doi.org\/10.7326\/M20-3012.","journal-title":"Ann Intern Med"},{"issue":"6490","key":"698_CR3","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1126\/science.abb3221","volume":"368","author":"R Li","year":"2020","unstructured":"Li R, Pei S, Chen B, et al. Substantial undocumented infection facilitates the rapid dissemination of novel coronavirus (SARS-CoV-2). Science. 2020;368(6490):489. https:\/\/doi.org\/10.1126\/science.abb3221.","journal-title":"Science"},{"key":"698_CR4","doi-asserted-by":"publisher","first-page":"190","DOI":"10.3389\/fmed.2020.00190","volume":"7","author":"H Li","year":"2020","unstructured":"Li H, Wang S, Zhong F, et al. Age-dependent risks of incidence and mortality of COVID-19 in Hubei Province and other parts of China. Front Med (Lausanne). 2020;7:190. https:\/\/doi.org\/10.3389\/fmed.2020.00190.","journal-title":"Front Med (Lausanne)"},{"issue":"9","key":"698_CR5","doi-asserted-by":"publisher","first-page":"e0238904","DOI":"10.1371\/journal.pone.0238904","volume":"15","author":"C Dudel","year":"2020","unstructured":"Dudel C, Riffe T, Acosta E, van Raalte A, Strozza C, Myrskyl\u00e4 M. Monitoring trends and differences in COVID-19 case-fatality rates using decomposition methods: Contributions of age structure and age-specific fatality. PLoS ONE. 2020;15(9):e0238904. https:\/\/doi.org\/10.1371\/journal.pone.0238904.","journal-title":"PLoS ONE"},{"key":"698_CR6","doi-asserted-by":"publisher","unstructured":"Moraga P, Ketcheson D, Ombao H, Duarte C. Assessing the age- and gender-dependence of the severity and case fatality rates of COVID-19 disease in Spain. 2020. https:\/\/doi.org\/10.12688\/wellcomeopenres.15996.1","DOI":"10.12688\/wellcomeopenres.15996.1"},{"key":"698_CR7","doi-asserted-by":"publisher","unstructured":"Byambasuren O, Dobler CC, Bell K, et al. Estimating The seroprevalence of SARS-CoV-2 infections: systematic review. 2020. medRxiv. https:\/\/doi.org\/10.1101\/2020.07.13.20153163","DOI":"10.1101\/2020.07.13.20153163"},{"key":"698_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/s1473-3099(20)30631-9","author":"RK Arora","year":"2020","unstructured":"Arora RK, Joseph A, Van Wyk J, et al. SeroTracker: a global SARS-CoV-2 seroprevalence dashboard. Lancet Infect Dis. 2020. https:\/\/doi.org\/10.1016\/s1473-3099(20)30631-9.","journal-title":"Lancet Infect Dis"},{"key":"698_CR9","doi-asserted-by":"publisher","unstructured":"Seoane B. A scaling approach to estimate the COVID-19 infection fatality ratio from incomplete data. medRxiv. 2020:2020.06.05.20123646. doi:https:\/\/doi.org\/10.1101\/2020.06.05.20123646","DOI":"10.1101\/2020.06.05.20123646"},{"key":"698_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/J.ANNEPIDEM.2020.06.004","author":"ES Rosenberg","year":"2020","unstructured":"Rosenberg ES, Tesoriero JM, Rosenthal EM, et al. Cumulative incidence and diagnosis of SARS-CoV-2 infection in New York. Ann Epidemiol. 2020. https:\/\/doi.org\/10.1016\/J.ANNEPIDEM.2020.06.004.","journal-title":"Ann Epidemiol."},{"key":"698_CR11","unstructured":"New York City Department of Health. COVID-19 Data. 2020."},{"key":"698_CR12","doi-asserted-by":"publisher","DOI":"10.1093\/INFDIS\/JIAA429","author":"BE Shook-Sa","year":"2020","unstructured":"Shook-Sa BE, Boyce RM, Aiello AE. Estimation without Representation: Early SARS-CoV-2 Seroprevalence Studies and the Path Forward. J Infect Dis. 2020. https:\/\/doi.org\/10.1093\/INFDIS\/JIAA429.","journal-title":"J Infect Dis."},{"key":"698_CR13","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.14017","author":"TS Brown","year":"2020","unstructured":"Brown TS, Walensky RP. Serosurveillance and the COVID-19 epidemic in the US: undetected, uncertain, and out of control. JAMA. 2020. https:\/\/doi.org\/10.1001\/jama.2020.14017.","journal-title":"JAMA"},{"key":"698_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32006-7","author":"B Flower","year":"2020","unstructured":"Flower B, Atchison C. SARS-CoV-2 antibody seroprevalence in patients receiving dialysis in the USA. Lancet. 2020. https:\/\/doi.org\/10.1016\/S0140-6736(20)32006-7.","journal-title":"Lancet"},{"key":"698_CR15","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.ijid.2020.09.1464","volume":"101","author":"G Meyerowitz-Katz","year":"2020","unstructured":"Meyerowitz-Katz G, Merone L. A systematic review and meta-analysis of published research data on COVID-19 infection fatality rates. Int J Infect Dis. 2020;101:138\u201348. https:\/\/doi.org\/10.1016\/j.ijid.2020.09.1464.","journal-title":"Int J Infect Dis"},{"key":"698_CR16","unstructured":"United Kingdom Parliament Office. Antibody tests for COVID-19. 2020."},{"key":"698_CR17","unstructured":"Organization for Economic Cooperation and Development. Member countries. 2020."},{"issue":"1","key":"698_CR18","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1111\/trf.12835","volume":"55","author":"S Lattimore","year":"2015","unstructured":"Lattimore S, Wickenden C, Brailsford SR. Blood donors in England and North Wales: demography and patterns of donation. Transfusion. 2015;55(1):91\u20139. https:\/\/doi.org\/10.1111\/trf.12835.","journal-title":"Transfusion"},{"key":"698_CR19","unstructured":"Public Health England. Sero-surveillance of COVID-19: week 22. 2020."},{"key":"698_CR20","unstructured":"United Kingdom Office for National Statistics. Coronavirus (COVID-19) infection survey: characteristics of people testing positive for COVID-19 in England, August 2020. 2020."},{"key":"698_CR21","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2020060827","author":"C Clarke","year":"2020","unstructured":"Clarke C, Prendecki M, Dhutia A, et al. High prevalence of asymptomatic COVID-19 infection in hemodialysis patients detected using serologic screening. J Am Soc Nephrol. 2020. https:\/\/doi.org\/10.1681\/ASN.2020060827.","journal-title":"J Am Soc Nephrol"},{"key":"698_CR22","doi-asserted-by":"publisher","unstructured":"Ward H, Atchison CJ, Whitaker M, et al. Antibody prevalence for SARS-CoV-2 in England following first peak of the pandemic: REACT2 study in 100,000 adults. medRxiv. 2020:2020.08.12.20173690. doi:https:\/\/doi.org\/10.1101\/2020.08.12.20173690","DOI":"10.1101\/2020.08.12.20173690"},{"key":"698_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32009-2","author":"S Anand","year":"2020","unstructured":"Anand S, Montez-Rath M, Han J, et al. Prevalence of SARS-CoV-2 antibodies in a large nationwide sample of patients on dialysis in the USA: a cross-sectional study. Lancet. 2020. https:\/\/doi.org\/10.1016\/S0140-6736(20)32009-2.","journal-title":"Lancet"},{"key":"698_CR24","unstructured":"Japan Ministry of Health Labour and Welfare. Updates on COVID-19 in Japan. 2020."},{"key":"698_CR25","doi-asserted-by":"publisher","first-page":"215013272094269","DOI":"10.1177\/2150132720942695","volume":"11","author":"M Takita","year":"2020","unstructured":"Takita M, Matsumura T, Yamamoto K, et al. Geographical profiles of COVID-19 outbreak in Tokyo: an analysis of the primary care clinic-based point-of-care antibody testing. J Prim Care Community Health. 2020;11:2150132720942695. https:\/\/doi.org\/10.1177\/2150132720942695.","journal-title":"J Prim Care Community Health"},{"key":"698_CR26","doi-asserted-by":"publisher","unstructured":"Snoeck CJ, Vaillant M, Abdelrahman T, et al. Prevalence of SARS-CoV-2 infection in the Luxembourgish population: the CON-VINCE study. 2020.\u00a0medRxiv. https:\/\/doi.org\/10.1101\/2020.05.11.20092916","DOI":"10.1101\/2020.05.11.20092916"},{"key":"698_CR27","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2020.4130","author":"FP Havers","year":"2020","unstructured":"Havers FP, Reed C, Lim T, et al. Seroprevalence of antibodies to SARS-CoV-2 in 10 sites in the United States, March 23\u2013May 12, 2020. JAMA Intern Med. 2020. https:\/\/doi.org\/10.1001\/jamainternmed.2020.4130.","journal-title":"JAMA Intern Med"},{"key":"698_CR28","unstructured":"University of Utah Health. Utah HERO project announces phase one findings. 2020."},{"key":"698_CR29","unstructured":"Our World in Data. Coronavirus (COVID-19) testing: tests per confirmed case. 2020. https:\/\/ourworldindata.org\/coronavirus-testing#tests-per-confirmed-case. Accessed 18 Aug."},{"issue":"24","key":"698_CR30","doi-asserted-by":"publisher","first-page":"2302","DOI":"10.1056\/NEJMoa2006100","volume":"382","author":"DF Gudbjartsson","year":"2020","unstructured":"Gudbjartsson DF, Helgason A, Jonsson H, et al. Spread of SARS-CoV-2 in the Icelandic population. N Engl J Med. 2020;382(24):2302\u201315. https:\/\/doi.org\/10.1056\/NEJMoa2006100.","journal-title":"N Engl J Med"},{"key":"698_CR31","unstructured":"Korea Center for Disease Control. Updates on COVID-19 in Korea as of July 9. 2020."},{"issue":"29","key":"698_CR32","doi-asserted-by":"publisher","first-page":"e269-e","DOI":"10.3346\/jkms.2020.35.e269","volume":"35","author":"SK Song","year":"2020","unstructured":"Song SK, Lee DH, Nam JH, et al. IgG Seroprevalence of COVID-19 among Individuals without a History of the Coronavirus Disease Infection in Daegu. Korea Journal of Korean medical science. 2020;35(29):e269-e. https:\/\/doi.org\/10.3346\/jkms.2020.35.e269.","journal-title":"Korea. Journal of Korean medical science."},{"issue":"8","key":"698_CR33","doi-asserted-by":"publisher","first-page":"e039856-e","DOI":"10.1136\/bmjopen-2020-039856","volume":"10","author":"AW Byrne","year":"2020","unstructured":"Byrne AW, McEvoy D, Collins AB, et al. Inferred duration of infectious period of SARS-CoV-2: rapid scoping review and analysis of available evidence for asymptomatic and symptomatic COVID-19 cases. BMJ Open. 2020;10(8):e039856-e. https:\/\/doi.org\/10.1136\/bmjopen-2020-039856.","journal-title":"BMJ Open."},{"issue":"6","key":"698_CR34","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1038\/s41591-020-0897-1","volume":"26","author":"QX Long","year":"2020","unstructured":"Long QX, Liu BZ, Deng HJ, et al. Antibody responses to SARS-CoV-2 in patients with COVID-19. Nat Med. 2020;26(6):845\u20138. https:\/\/doi.org\/10.1038\/s41591-020-0897-1.","journal-title":"Nat Med"},{"issue":"22","key":"698_CR35","doi-asserted-by":"publisher","first-page":"2249","DOI":"10.1001\/jama.2020.8259","volume":"323","author":"N Sethuraman","year":"2020","unstructured":"Sethuraman N, Jeremiah SS, Ryo A. Interpreting diagnostic tests for SARS-CoV-2. JAMA. 2020;323(22):2249\u201351. https:\/\/doi.org\/10.1001\/jama.2020.8259.","journal-title":"JAMA"},{"key":"698_CR36","doi-asserted-by":"publisher","DOI":"10.3201\/eid2610.202211","author":"PG Choe","year":"2020","unstructured":"Choe PG, Kang CK, Suh HJ, et al. Antibody responses to SARS-CoV-2 at 8 weeks postinfection in asymptomatic patients. Emerg Infect Dis J. 2020. https:\/\/doi.org\/10.3201\/eid2610.202211.","journal-title":"Emerg Infect Dis J"},{"key":"698_CR37","doi-asserted-by":"publisher","unstructured":"Ripperger TJ, Uhrlaub JL, Watanabe M, et al. Detection, prevalence, and duration of humoral responses to SARS-CoV-2 under conditions of limited population exposure. medRxiv. 2020:2020.08.14.20174490. doi:https:\/\/doi.org\/10.1101\/2020.08.14.20174490","DOI":"10.1101\/2020.08.14.20174490"},{"key":"698_CR38","unstructured":"U.S. Center for Disease Control and Prevention. COVID-19 pandemic planning scenarios. 2020."},{"issue":"4","key":"698_CR39","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1177\/1536867X0800800403","volume":"8","author":"RM Harbord","year":"2008","unstructured":"Harbord RM, Higgins JPT. Meta-regression in Stata. Stata J. 2008;8(4):493\u2013519.","journal-title":"Stata J"},{"issue":"1","key":"698_CR40","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1111\/j.1467-985X.2008.00552.x","volume":"172","author":"JPT Higgins","year":"2009","unstructured":"Higgins JPT, Thompson SG, Spiegelhalter DJ. A re-evaluation of random-effects meta-analysis. J R Stat Soc Ser A Stat Soc. 2009;172(1):137\u201359. https:\/\/doi.org\/10.1111\/j.1467-985X.2008.00552.x.","journal-title":"J R Stat Soc Ser A Stat Soc"},{"key":"698_CR41","doi-asserted-by":"publisher","unstructured":"Chamie G, Marquez C, Crawford E, et al. SARS-CoV-2 community transmission\u00a0disproportionately affects Latinx population during shelter-in-place in San Francisco. Clin Infect Dis. 2020. https:\/\/doi.org\/10.1093\/cid\/ciaa1234","DOI":"10.1093\/cid\/ciaa1234"},{"key":"698_CR42","unstructured":"Czech Ministry of Health. Collective immunity study SARS-CoV-2: Czech prevalence. 2020."},{"key":"698_CR43","unstructured":"Denmark State Blood Institute. Notat: Nye forel\u00f8bige resultater fra den repr\u00e6sentative seropr\u00e6valensunders\u00f8gelse af COVID-19. 2020."},{"key":"698_CR44","doi-asserted-by":"publisher","unstructured":"Dimeglio C, Loubes J-M, Miedoug\u00e9 M, Herin F, Soulat J-M, Izopet J. The real seroprevalence of SARS-CoV-2 in France and its consequences for virus dynamics. 2020.\u00a0J Infect. 81:318\u2013356. https:\/\/doi.org\/10.1016\/j.jinf.2020.04.031","DOI":"10.1016\/j.jinf.2020.04.031"},{"key":"698_CR45","unstructured":"Jersey Health & Community Services. Prevalence of antibodies: community survey round 2. 2020."},{"key":"698_CR46","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1038\/s41586-020-2488-1","volume":"584","author":"E Lavezzo","year":"2020","unstructured":"Lavezzo E, Franchin E, Ciavarella C, et al. Suppression of COVID-19 outbreak in the municipality of Vo, Italy. Nature. 2020;584:425\u20139. https:\/\/doi.org\/10.1038\/s41586-020-2488-1.","journal-title":"Nature"},{"key":"698_CR47","doi-asserted-by":"publisher","unstructured":"Mahajan S, Srinivasan R, Redlich CA, et al. Seroprevalence of SARS-CoV-2-specific IgG antibodies among adults living in connecticut between March 1 and June 1, 2020: post-infection prevalence (PIP) study. medRxiv. 2020:2020.08.04.20168203. https:\/\/doi.org\/10.1101\/2020.08.04.20168203","DOI":"10.1101\/2020.08.04.20168203"},{"key":"698_CR48","doi-asserted-by":"publisher","unstructured":"McLaughlin CC, Doll MK, Morrison KT, et al. High community SARS-CoV-2 antibody seroprevalence in a ski resort community, Blaine County, Idaho, US. Preliminary results. medRxiv. 2020. doi:https:\/\/doi.org\/10.1101\/2020.07.19.20157198","DOI":"10.1101\/2020.07.19.20157198"},{"key":"698_CR49","doi-asserted-by":"publisher","unstructured":"Nawa N, Kuramochi J, Sonoda S, et al. Seroprevalence of SARS-CoV-2 IgG Antibodies in Utsunomiya City, Greater Tokyo, after first pandemic in 2020 (U-CORONA): a household- and population-based study. medRxiv. 2020. https:\/\/doi.org\/10.1101\/2020.07.20.20155945","DOI":"10.1101\/2020.07.20.20155945"},{"key":"698_CR50","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9020419","author":"H Nishiura","year":"2020","unstructured":"Nishiura H, Kobayashi T, Yang Y, et al. The rate of underascertainment of novel coronavirus (2019-nCoV) infection: estimation using Japanese passengers data on evacuation flights. J Clin Med. 2020. https:\/\/doi.org\/10.3390\/jcm9020419.","journal-title":"J Clin Med."},{"key":"698_CR51","unstructured":"Norrbotten Region. Forekomst av antikroppar mot covid-19\u2014Norrbottens befolkning maj 2020. 2020."},{"key":"698_CR52","unstructured":"Norway Public Health Institute. Truleg berre ein liten andel av befolkninga som har vore smitta av koronavirus. 2020."},{"key":"698_CR53","unstructured":"Oklahoma State Department of Health. Weekly epidemiology and surveillance report. 2020."},{"key":"698_CR54","unstructured":"Oregon State University. TRACE results suggest 17% of Hermiston community infected with SARS-CoV-2. 2020."},{"key":"698_CR55","doi-asserted-by":"publisher","DOI":"10.3201\/EID2611.202736","author":"MS Petersen","year":"2020","unstructured":"Petersen MS, Str\u00f8m M, Christiansen DH, et al. Seroprevalence of SARS-CoV-2-specific antibodies, Faroe Islands. Emerg Infect Dis. 2020. https:\/\/doi.org\/10.3201\/EID2611.202736.","journal-title":"Emerg Infect Dis"},{"key":"698_CR56","unstructured":"Rhode Island Department of Health. COVID-19 serology testing brief. 2020."},{"key":"698_CR57","unstructured":"Riverside County Joint Information Center. Antibody study shows coronavirus spread wider in Riverside County. 2020."},{"key":"698_CR58","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1093\/infdis\/jiaa579","volume":"222","author":"V Naranbhai","year":"2020","unstructured":"Naranbhai V, Chang C, Beltran W, et al. High seroprevalence of anti-SARS-CoV-2 antibodies in Chelsea, Massachusetts. J Infect Dis. 2020;222:1955\u20139. https:\/\/doi.org\/10.1093\/infdis\/jiaa579.","journal-title":"J Infect Dis."},{"key":"698_CR59","unstructured":"San Miguel County Department of Health & Environment. IgG antibody tests: statistics and demographics. 2020."},{"key":"698_CR60","first-page":"2020","volume-title":"Low SARS-CoV-2 sero-prevalence based on anonymized residual sero-survey before and after first wave measures in British Columbia","author":"DM Skowronski","year":"2020","unstructured":"Skowronski DM, Sekirov I, Sabaiduc S, et al. Low SARS-CoV-2 sero-prevalence based on anonymized residual sero-survey before and after first wave measures in British Columbia. Canada: March-May; 2020. p. 2020."},{"key":"698_CR61","unstructured":"Slovenia Government Communication Office. First study carried out on herd immunity of the population in the whole territory of Slovenia. 2020."},{"key":"698_CR62","doi-asserted-by":"publisher","unstructured":"Stadlbauer D, Tan J, Jiang K, et al. Seroconversion of a city: longitudinal monitoring of SARS-CoV-2 seroprevalence in New York City. medRxiv. 2020:2020.06.28.20142190. https:\/\/doi.org\/10.1101\/2020.06.28.20142190","DOI":"10.1101\/2020.06.28.20142190"},{"key":"698_CR63","unstructured":"Stockholm Region. L\u00e4gesrapport om arbetet med det nya coronaviruset. 2020."},{"key":"698_CR64","doi-asserted-by":"publisher","unstructured":"Streeck H, Schulte B, Kuemmerer B, et al. Infection fatality rate of SARS-CoV-2 infection in a German community with a super-spreading event. 2020. Nat Commun 11:5829. https:\/\/doi.org\/10.1038\/s41467-020-19509-y.","DOI":"10.1038\/s41467-020-19509-y"},{"key":"698_CR65","unstructured":"University of Miami. SPARK-C: understanding the burden of COVID-19 in Miami-Dade County through rapid serological testing of a representative random sample. 2020."},{"key":"698_CR66","unstructured":"Washoe County Health District. Seroprevalence of SARS-CoV-2 specific antibodies among adults in Washoe County, Nevada on June 9\u201310, 2020. 2020."},{"key":"698_CR67","doi-asserted-by":"publisher","unstructured":"Weis S, Scherag A, Baier M, et al. Seroprevalence of SARS-CoV-2 antibodies in an entirely PCR-sampled and quarantined community after a COVID-19 outbreak: the CoNAN study.\u00a0medRxiv. 2020. https:\/\/doi.org\/10.1101\/2020.07.15.20154112","DOI":"10.1101\/2020.07.15.20154112"},{"key":"698_CR68","doi-asserted-by":"crossref","unstructured":"Wells PM, Doores KM, Couvreur S, et al. Estimates of the rate of infection and asymptomatic COVID-19 disease in a population sample from SE England. 2020.","DOI":"10.1016\/j.jinf.2020.10.011"},{"key":"698_CR69","unstructured":"Sweden Public Health Authority. the infection fatality rate of COVID-19 in Stockholm: technical report. 2020."},{"key":"698_CR70","doi-asserted-by":"publisher","DOI":"10.3201\/eid2611.203029","author":"AK Feehan","year":"2020","unstructured":"Feehan AK, Fort D, Garcia-Diaz J, et al. Seroprevalence of SARS-CoV-2 and infection fatality ratio, Orleans and Jefferson Parishes, Louisiana, USA, May 2020. Emerg Infect Dis. 2020. https:\/\/doi.org\/10.3201\/eid2611.203029.","journal-title":"Emerg Infect Dis."},{"key":"698_CR71","unstructured":"Giustizia News. Coronavirus, l'incubo senza fine di Ariano Irpino: 60 positivi al tampone dopo i test sierologici. May 28."},{"key":"698_CR72","unstructured":"Austria Statistik. COVID-19 prevalence study: a maximum of 0.15% of the population in Austria infected with SARS-CoV-2. 2020."},{"key":"698_CR73","unstructured":"Saltzman J. Study: 1 out of 10 residents in 4 neighborhoods unwittingly had coronavirus. Boston Globe. 2020 May 15."},{"key":"698_CR74","unstructured":"Micolitti A. Caldari Ortona: 12% cittadini sottoposti a test sierologici positivi con anticorpi al Covid 19. Rete8. 2020 June 3."},{"key":"698_CR75","unstructured":"Finland National Institute for Health and Welfare. Weekly report of THL serological population study of the coronavirus epidemic. 2020."},{"issue":"31","key":"698_CR76","doi-asserted-by":"publisher","first-page":"2001369","DOI":"10.2807\/1560-7917.ES.2020.25.31.2001369","volume":"25","author":"Z Bogogiannidou","year":"2020","unstructured":"Bogogiannidou Z, Vontas A, Dadouli K, et al. Repeated leftover serosurvey of SARS-CoV-2 IgG antibodies, Greece, March and April 2020. Eurosurveillance. 2020;25(31):2001369. https:\/\/doi.org\/10.2807\/1560-7917.ES.2020.25.31.2001369.","journal-title":"Eurosurveillance."},{"key":"698_CR77","unstructured":"Times of Israel Staff. Coronavirus : Isra\u00ebl est encore loin de l\u2019immunit\u00e9 de groupe. Times of Israel. 2020 July 23."},{"key":"698_CR78","doi-asserted-by":"publisher","unstructured":"Aziz NA, Corman VM, Echterhoff AKC, et al. Seroprevalence and correlates of SARS-CoV-2 neutralizing antibodies: results from a population-based study in Bonn, Germany. medRxiv. 2020:2020.08.24.20181206. doi:https:\/\/doi.org\/10.1101\/2020.08.24.20181206","DOI":"10.1101\/2020.08.24.20181206"},{"key":"698_CR79","unstructured":"CBC News. Serology study gives officials first look at spread of COVID-19 through Alberta's population. 2020 July 30."},{"key":"698_CR80","doi-asserted-by":"publisher","unstructured":"Feehan AK, Velasco C, Fort D, et al. Racial and workplace disparities in seroprevalence of SARS-CoV-2 in Baton Rouge, Louisiana, July 15\u201331, 2020. medRxiv. 2020:2020.08.26.20180968. doi:https:\/\/doi.org\/10.1101\/2020.08.26.20180968","DOI":"10.1101\/2020.08.26.20180968"},{"key":"698_CR81","doi-asserted-by":"publisher","unstructured":"Hicks S, Pohl K, Neeman T, et al. A dual antigen ELISA allows the assessment of SARS-CoV-2 antibody seroprevalence in a low transmission setting. medRxiv. 2020:2020.09.09.20191031. doi:https:\/\/doi.org\/10.1101\/2020.09.09.20191031","DOI":"10.1101\/2020.09.09.20191031"},{"issue":"1","key":"698_CR82","doi-asserted-by":"publisher","first-page":"1806505","DOI":"10.1080\/20008686.2020.1806505","volume":"10","author":"\u00c5 Lundkvist","year":"2020","unstructured":"Lundkvist \u00c5, Hanson S, Olsen B. Pronounced difference in Covid-19 antibody prevalence indicates cluster transmission in Stockholm, Sweden. Infect Ecol Epidemiol. 2020;10(1):1806505. https:\/\/doi.org\/10.1080\/20008686.2020.1806505.","journal-title":"Infect Ecol Epidemiol"},{"key":"698_CR83","unstructured":"University of Louisville School of Medicine. Phase II results of Co-Immunity Project show higher-than-expected rates of exposure to novel coronavirus in Jefferson County. 2020."},{"key":"698_CR84","doi-asserted-by":"publisher","unstructured":"van den Broek-Altenburg E, Atherly A, Diehl S, et al. Risk factors for COVID-19: community exposure and mask-wearing. 2020. doi:https:\/\/doi.org\/10.2139\/ssrn.3676570","DOI":"10.2139\/ssrn.3676570"},{"key":"698_CR85","doi-asserted-by":"publisher","unstructured":"Knabl L, Mitra T, Kimpel J, et al. High SARS-CoV-2 Seroprevalence in children and adults in the Austrian ski resort Ischgl. medRxiv. 2020:2020.08.20.20178533. doi:https:\/\/doi.org\/10.1101\/2020.08.20.20178533","DOI":"10.1101\/2020.08.20.20178533"},{"key":"698_CR86","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiaa579","author":"V Naranbhai","year":"2020","unstructured":"Naranbhai V, Chang CC, Beltran WFG, et al. High seroprevalence of anti-SARS-CoV-2 antibodies in Chelsea, Massachusetts. J Infect Dis. 2020. https:\/\/doi.org\/10.1093\/infdis\/jiaa579.","journal-title":"J Infect Dis"},{"key":"698_CR87","doi-asserted-by":"publisher","unstructured":"Fenwick C, Croxatto A, Coste AT, et al. Changes in SARS-CoV-2 antibody responses impact the estimates of infections in population-based seroprevalence studies. medRxiv. 2020:2020.07.14.20153536. doi:https:\/\/doi.org\/10.1101\/2020.07.14.20153536","DOI":"10.1101\/2020.07.14.20153536"},{"key":"698_CR88","doi-asserted-by":"publisher","unstructured":"Figueiredo-Campos P, Blankenhaus B, Mota C, et al. Seroprevalence of anti-SARS-CoV-2 antibodies in COVID-19 patients and healthy volunteers. medRxiv. 2020:2020.08.30.20184309. doi:https:\/\/doi.org\/10.1101\/2020.08.30.20184309","DOI":"10.1101\/2020.08.30.20184309"},{"key":"698_CR89","doi-asserted-by":"publisher","unstructured":"Hibino S, Hayashida K, Ahn AC, Hayashida Y. Dynamic change of COVID-19 seroprevalence among asymptomatic population in Tokyo during the second wave. medRxiv. 2020:2020.09.21.20198796. doi:https:\/\/doi.org\/10.1101\/2020.09.21.20198796","DOI":"10.1101\/2020.09.21.20198796"},{"key":"698_CR90","unstructured":"Northeast Texas Public Health Department. Hideaway COVID-19 antibody testing program. 2020."},{"key":"698_CR91","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2020.10.004","author":"TJ Ripperger","year":"2020","unstructured":"Ripperger TJ, Uhrlaub JL, Watanabe M, et al. Orthogonal SARS-CoV-2 Serological Assays Enable Surveillance of Low Prevalence Communities and Reveal Durable Humoral Immunity. Immunity. 2020. https:\/\/doi.org\/10.1016\/j.immuni.2020.10.004.","journal-title":"Immunity"},{"key":"698_CR92","doi-asserted-by":"publisher","DOI":"10.1016\/J.DIAGMICROBIO.2020.11512","author":"J Reifer","year":"2020","unstructured":"Reifer J, Hayum N, Heszkel B, Klagsbald I, Streva VA. SARS-CoV-2 IgG antibody responses in New York City. Diagn Microbiol Infect Dis. 2020. https:\/\/doi.org\/10.1016\/J.DIAGMICROBIO.2020.11512.","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"4","key":"698_CR93","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1007\/s11357-020-00226-9","volume":"42","author":"B Merkely","year":"2020","unstructured":"Merkely B, Szabo AJ, Kosztin A, et al. Novel coronavirus epidemic in the Hungarian population, a cross-sectional nationwide survey to support the exit policy in Hungary. Geroscience. 2020;42(4):1063\u201374. https:\/\/doi.org\/10.1007\/s11357-020-00226-9.","journal-title":"Geroscience"},{"key":"698_CR94","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.15585\/mmwr.mm6932a4","volume":"69","author":"M Sutton","year":"2020","unstructured":"Sutton M, Cieslak P, Linder M. Seroprevalence estimates of SARS-CoV-2 infection in convenience sample\u2014Oregon, May 11\u2013June 15. Morb Mortal Wkly Report. 2020;69:1100\u20131. https:\/\/doi.org\/10.15585\/mmwr.mm6932a4.","journal-title":"Morb Mortal Wkly Report."},{"key":"698_CR95","doi-asserted-by":"publisher","unstructured":"Armann JP, Unrath M, Kirsten C, Lueck C, Dalpke A, Berner R. Anti-SARS-CoV-2 IgG antibodies in adolescent students and their teachers in Saxony, Germany (SchoolCoviDD19): very low seropraevalence and transmission rates. 2020. doi:https:\/\/doi.org\/10.1101\/2020.07.16.20155143","DOI":"10.1101\/2020.07.16.20155143"},{"key":"698_CR96","doi-asserted-by":"publisher","unstructured":"Bendavid E, Mulaney B, Sood N, et al. COVID-19 antibody seroprevalence in Santa Clara County, California. medRxiv. 2020. https:\/\/doi.org\/10.1101\/2020.04.14.20062463","DOI":"10.1101\/2020.04.14.20062463"},{"key":"698_CR97","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00941-20","author":"A Bryan","year":"2020","unstructured":"Bryan A, Pepper G, Wener MH, et al. Performance characteristics of the Abbott Architect SARS-CoV-2 IgG assay and seroprevalence in Boise, Idaho. J Clin Microbiol. 2020. https:\/\/doi.org\/10.1128\/JCM.00941-20.","journal-title":"J Clin Microbiol."},{"key":"698_CR98","doi-asserted-by":"publisher","DOI":"10.1093\/CID\/CIAA849","author":"C Erikstrup","year":"2020","unstructured":"Erikstrup C, Hother CE, Pedersen OBV, et al. Estimation of SARS-CoV-2 infection fatality rate by real-time antibody screening of blood donors. Clin Infect Dis. 2020. https:\/\/doi.org\/10.1093\/CID\/CIAA849.","journal-title":"Clin Infect Dis"},{"key":"698_CR99","doi-asserted-by":"publisher","unstructured":"Fiore J, Centra M, de Carlo A, et al. Far away from herd immunity to SARS-CoV-2: results from a survey in healthy blood donors in southeastern Italy. 2020. doi:https:\/\/doi.org\/10.1101\/2020.06.17.20133678","DOI":"10.1101\/2020.06.17.20133678"},{"key":"698_CR100","doi-asserted-by":"publisher","DOI":"10.2807\/1560-7917.ES.2020.25.28.2001285","author":"B Fischer","year":"2020","unstructured":"Fischer B, Knabbe C, Vollmer T. SARS-CoV-2 IgG seroprevalence in blood donors located in three different federal states, Germany, March to June 2020. Euro Surveill. 2020. https:\/\/doi.org\/10.2807\/1560-7917.ES.2020.25.28.2001285.","journal-title":"Euro Surveill."},{"key":"698_CR101","doi-asserted-by":"publisher","unstructured":"Fontanet A, Tondeur L, Madec Y, et al. Cluster of COVID-19 in northern France: a retrospective closed cohort study. medRxiv. 2020:2020.04.18.20071134. doi:https:\/\/doi.org\/10.1101\/2020.04.18.20071134","DOI":"10.1101\/2020.04.18.20071134"},{"key":"698_CR102","doi-asserted-by":"publisher","unstructured":"Kraehling V, Kern M, Halwe S, et al. Epidemiological study to detect active SARS-CoV-2 infections and seropositive persons in a selected cohort of employees in the Frankfurt am Main metropolitan area. medRxiv. 2020.\u00a0https:\/\/doi.org\/10.1101\/2020.05.20.20107730","DOI":"10.1101\/2020.05.20.20107730"},{"key":"698_CR103","doi-asserted-by":"publisher","unstructured":"Nesbitt DJ, Jin D, Hogan JW, et al. Low seroprevalence of SARS-CoV-2 in Rhode Island blood donors determined using multiple serological assay formats. medRxiv. 2020. https:\/\/doi.org\/10.1101\/2020.07.20.20157743","DOI":"10.1101\/2020.07.20.20157743"},{"key":"698_CR104","doi-asserted-by":"publisher","unstructured":"Ng D, Goldgof G, Shy B, et al. SARS-CoV-2 seroprevalence and neutralizing activity in donor and patient blood from the San Francisco Bay Area. medRxiv. 2020. doi:https:\/\/doi.org\/10.1101\/2020.05.19.20107482","DOI":"10.1101\/2020.05.19.20107482"},{"key":"698_CR105","doi-asserted-by":"publisher","DOI":"10.2807\/1560-7917.ES.2020.25.24.2001031","author":"E Percivalle","year":"2020","unstructured":"Percivalle E, Cambie G, Cassaniti I, et al. Prevalence of SARS-CoV-2 specific neutralising antibodies in blood donors from the Lodi Red Zone in Lombardy, Italy, as at 06 April 2020. Euro Surveill. 2020. https:\/\/doi.org\/10.2807\/1560-7917.ES.2020.25.24.2001031.","journal-title":"Euro Surveill."},{"key":"698_CR106","doi-asserted-by":"publisher","unstructured":"Slot E, Hogema BM, Reusken CBEM, et al. Herd immunity is not a realistic exit strategy during a COVID-19 outbreak. 2020. doi:https:\/\/doi.org\/10.21203\/rs.3.rs-25862\/v1","DOI":"10.21203\/rs.3.rs-25862\/v1"},{"key":"698_CR107","doi-asserted-by":"publisher","unstructured":"Thompson CP, Grayson N, Paton R, et al. Detection of neutralising antibodies to SARS coronavirus 2 to determine population exposure in Scottish blood donors between March and May 2020. medRxiv. 2020:2020.04.13.20060467. doi:https:\/\/doi.org\/10.1101\/2020.04.13.20060467","DOI":"10.1101\/2020.04.13.20060467"},{"key":"698_CR108","doi-asserted-by":"publisher","unstructured":"Valenti L, Bergna A, Pelusi S, et al. SARS-CoV-2 seroprevalence trends in healthy blood donors during the COVID-19 Milan outbreak. medRxiv. 2020. https:\/\/doi.org\/10.1101\/2020.05.11.20098442","DOI":"10.1101\/2020.05.11.20098442"},{"key":"698_CR109","doi-asserted-by":"publisher","unstructured":"Doi A, Iwata K, Kuroda H, et al. Estimation of seroprevalence of novel coronavirus disease (COVID-19) using preserved serum at an outpatient setting in Kobe, Japan: a cross-sectional study. medRxiv. 2020. https:\/\/doi.org\/10.1101\/2020.04.26.20079822","DOI":"10.1101\/2020.04.26.20079822"},{"key":"698_CR110","doi-asserted-by":"publisher","unstructured":"Emmenegger M, Cecco ED, Lamparter D, et al. Population-wide evolution of SARS-CoV-2 immunity tracked by a ternary immunoassay. medRxiv. 2020. https:\/\/doi.org\/10.1101\/2020.05.31.20118554","DOI":"10.1101\/2020.05.31.20118554"},{"key":"698_CR111","unstructured":"Canadian Blood Services. COVID-19 seroprevalence report\u2014August 19, 2020. 2020."},{"key":"698_CR112","doi-asserted-by":"publisher","unstructured":"Poletti P, Tirani M, Cereda D, et al. Age-specific SARS-CoV-2 infection fatality ratio and associated risk factors, Italy, February to April 2020. Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin. 2020;25(31):2001383. doi:https:\/\/doi.org\/10.2807\/1560-7917.ES.2020.25.31.2001383","DOI":"10.2807\/1560-7917.ES.2020.25.31.2001383"},{"key":"698_CR113","doi-asserted-by":"publisher","unstructured":"Rigatti SJ, Stout R. SARS-CoV-2 antibody prevalence and association with routine laboratory values in a life insurance applicant population. medRxiv. 2020:2020.09.09.20191296. doi:https:\/\/doi.org\/10.1101\/2020.09.09.20191296","DOI":"10.1101\/2020.09.09.20191296"},{"key":"698_CR114","doi-asserted-by":"publisher","unstructured":"Toenshoff B, Muller B, Elling R, et al. Prevalence of SARS-CoV-2 infection in children and their parents in Southwest Germany. 2020. doi:https:\/\/doi.org\/10.2139\/ssrn.3668418","DOI":"10.2139\/ssrn.3668418"},{"key":"698_CR115","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.18598","author":"RY Dodd","year":"2020","unstructured":"Dodd RY, Xu M, Stramer SL. Change in donor characteristics and antibodies to SARS-CoV-2 in donated blood in the US, June\u2013August 2020. JAMA. 2020. https:\/\/doi.org\/10.1001\/jama.2020.18598.","journal-title":"JAMA"},{"key":"698_CR116","doi-asserted-by":"publisher","unstructured":"Ulyte A, Radtke T, Abela IA, et al. Variation in SARS-CoV-2 seroprevalence in school-children across districts, schools and classes. medRxiv. 2020:2020.09.18.20191254. doi:https:\/\/doi.org\/10.1101\/2020.09.18.20191254","DOI":"10.1101\/2020.09.18.20191254"},{"key":"698_CR117","doi-asserted-by":"publisher","unstructured":"Vassallo RR, Bravo MD, Dumont LJ, Hazegh K, Kamel H. Seroprevalence of antibodies to SARS-CoV-2 in US blood donors. medRxiv. 2020:2020.09.17.20195131. doi:https:\/\/doi.org\/10.1101\/2020.09.17.20195131","DOI":"10.1101\/2020.09.17.20195131"},{"key":"698_CR118","doi-asserted-by":"publisher","unstructured":"Biggs HM. Estimated community seroprevalence of SARS-CoV-2 antibodies\u2014two Georgia Counties, April 28\u2013May 3, 2020. Morb Mortal Wkly Rep 2020;69(29):965\u201370. doi:https:\/\/doi.org\/10.15585\/MMWR.MM6929E2","DOI":"10.15585\/MMWR.MM6929E2"},{"key":"698_CR119","unstructured":"Italy National Institute of Statistics. Primi risultati dell'indagine di sieroprevalenza sul SARS-CoV-2. 2020."},{"key":"698_CR120","doi-asserted-by":"publisher","unstructured":"Pastor-Barriuso R, Perez-Gomez B, Hernan MA, et al. SARS-CoV-2 infection fatality risk in a nationwide seroepidemiological study. medRxiv. 2020:2020.08.06.20169722. doi:https:\/\/doi.org\/10.1101\/2020.08.06.20169722","DOI":"10.1101\/2020.08.06.20169722"},{"key":"698_CR121","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(20)30584-3","author":"J Perez-Saez","year":"2020","unstructured":"Perez-Saez J, Lauer SA, Kaiser L, et al. Serology-informed estimates of SARS-CoV-2 infection fatality risk in Geneva, Switzerland. Lancet Infect Dis. 2020. https:\/\/doi.org\/10.1016\/S1473-3099(20)30584-3.","journal-title":"Lancet Infect Dis."},{"key":"698_CR122","unstructured":"Netherlands National Institute for Public Health and the Environment. Children and COVID-19. 2020."},{"key":"698_CR123","unstructured":"Portugal National Institute of Health. Relat\u00f3rio de Apresenta\u00e7\u00e3o dos Resultados Preliminares do Primeiro Inqu\u00e9rito Serol\u00f3gico Nacional COVID-19. 2020."},{"issue":"29","key":"698_CR124","doi-asserted-by":"publisher","first-page":"960","DOI":"10.15585\/MMWR.MM6929E1","volume":"69","author":"N Menachemi","year":"2020","unstructured":"Menachemi N, Yiannoutsos CT, Dixon BE, et al. Population point prevalence of SARS-CoV-2 infection based on a statewide random sample\u2014Indiana, April 25\u201329, 2020. Morb Mortal Wkly Rep. 2020;69(29):960\u20134. https:\/\/doi.org\/10.15585\/MMWR.MM6929E1.","journal-title":"Morb Mortal Wkly Rep"},{"key":"698_CR125","unstructured":"Ireland Health Service Executive. Preliminary report of the results of the study to investigate COVID-19 infection in people living in Ireland (SCOPI): a national seroprevalence study, June\u2013July 2020. 2020."},{"key":"698_CR126","doi-asserted-by":"publisher","unstructured":"Waterfield T, Watson C, Moore R, et al. Seroprevalence of SARS-CoV-2 antibodies in children: a prospective multicentre cohort study. medRxiv. 2020:2020.08.31.20183095. doi:https:\/\/doi.org\/10.1101\/2020.08.31.20183095","DOI":"10.1101\/2020.08.31.20183095"},{"key":"698_CR127","doi-asserted-by":"publisher","unstructured":"Carrat F, de Lamballerie X, Rahib D, et al. Seroprevalence of SARS-CoV-2 among adults in three regions of France following the lockdown and associated risk factors: a multicohort study. medRxiv. 2020:2020.09.16.20195693. doi:https:\/\/doi.org\/10.1101\/2020.09.16.20195693","DOI":"10.1101\/2020.09.16.20195693"},{"key":"698_CR128","doi-asserted-by":"publisher","unstructured":"Molenberghs G, Faes C, Aerts J, et al. Belgian Covid-19 mortality, excess deaths, number of deaths per million, and infection fatality rates (8 March\u20139 May 2020). medRxiv. 2020. https:\/\/doi.org\/10.1101\/2020.06.20.20136234","DOI":"10.1101\/2020.06.20.20136234"},{"key":"698_CR129","unstructured":"Sweden Public Health Authority. Seroprevalence of antibodies following COVID-19 infection in blood samples from outpatient care, interim report 1, updated on June 18 using data thru week 21\u2014P\u00e5visning av antikroppar efter genomg\u00e5ngen covid-19 i blodprov fr\u00e5n \u00f6ppenv\u00e5rden, delrapport 1 - uppdaterad 2020-06-18 med data f\u00f6r prover insamlade vecka 21. 2020."},{"key":"698_CR130","unstructured":"Ontario Public Health. COVID-19 seroprevalence in Ontario: March 27, 2020 to June 30, 2020. 2020."},{"key":"698_CR131","unstructured":"Australia Department of Health. Coronavirus (COVID-19) current situation and case numbers. 2020."},{"key":"698_CR132","unstructured":"Iceland Directorate of Health. COVID-19 in Iceland\u2014statistics 28 Feb to 14 June 2020. 2020."},{"key":"698_CR133","unstructured":"Korea Center for Disease Control. Weekly report on the COVID-19 situation in the Republic of Korea. 2020."},{"key":"698_CR134","unstructured":"Lithuania Central Registry. Koronaviruso (COVID-19) Lietuvoje statistika. 2020."},{"key":"698_CR135","unstructured":"New Zealand Ministry of Health. COVID-19 current cases. 2020."},{"key":"698_CR136","unstructured":"United Kingdom BioBank. UK Biobank SARS-CoV-2 serology study weekly report\u201421 July 2020. 2020."},{"key":"698_CR137","doi-asserted-by":"publisher","DOI":"10.2807\/1560-7917.ES.2020.25.10.2000180","author":"K Mizumoto","year":"2020","unstructured":"Mizumoto K, Kagaya K, Zarebski A, Chowell G. Estimating the asymptomatic proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess cruise ship, Yokohama, Japan, 2020. Eurosurveillance. 2020. https:\/\/doi.org\/10.2807\/1560-7917.ES.2020.25.10.2000180.","journal-title":"Eurosurveillance"},{"key":"698_CR138","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2020.09.021","author":"G Pagani","year":"2020","unstructured":"Pagani G, Conti F, Giacomelli A, et al. Seroprevalence of SARS-CoV-2 significantly varies with age: preliminary results from a mass population screening. J Infect. 2020. https:\/\/doi.org\/10.1016\/j.jinf.2020.09.021.","journal-title":"J Infect"},{"key":"698_CR139","unstructured":"France Public Health. COVID-19: point \u00e9pid\u00e9miologique du 9 juillet 2020. 2020."},{"key":"698_CR140","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-0962-9","author":"NG Davies","year":"2020","unstructured":"Davies NG, Klepac P, Liu Y, et al. Age-dependent effects in the transmission and control of COVID-19 epidemics. Nat Med. 2020. https:\/\/doi.org\/10.1038\/s41591-020-0962-9.","journal-title":"Nat Med"},{"key":"698_CR141","doi-asserted-by":"crossref","unstructured":"Acemoglu D, Chernozhukov V, Werning I, Whinston M. Optimal targeted lockdowns in a multi-group SIR model. National Bureau of Economic Research Working Paper 27102. 2020.","DOI":"10.3386\/w27102"},{"key":"698_CR142","unstructured":"U.S. National Center for Health Statistics. Underlying cause of death, 1999\u20132018. 2020."},{"key":"698_CR143","unstructured":"United Kingdom Office of National Statistics. Mortality statistics\u2014underlying cause, sex and age. 2020."},{"key":"698_CR144","unstructured":"World Health Organization. Coronavirus disease (COVID-19): similarities and differences with influenza. 2020."},{"key":"698_CR145","doi-asserted-by":"publisher","DOI":"10.7326\/M20-5352","author":"J Blackburn","year":"2020","unstructured":"Blackburn J, Yiannoutsos CT, Carroll AE, Halverson PK, Menachemi N. Infection fatality ratios for COVID-19 among noninstitutionalized persons 12 and older: results of a random-sample prevalence study. Ann Intern Med. 2020. https:\/\/doi.org\/10.7326\/M20-5352.","journal-title":"Ann Intern Med"},{"key":"698_CR146","doi-asserted-by":"publisher","unstructured":"O'Driscoll M, Ribeiro Dos Santos G, Wang L, et al. Age-specific mortality and immunity patterns of SARS-CoV-2 infection in 45 countries. medRxiv. 2020:2020.08.24.20180851. doi:https:\/\/doi.org\/10.1101\/2020.08.24.20180851","DOI":"10.1101\/2020.08.24.20180851"},{"key":"698_CR147","doi-asserted-by":"publisher","unstructured":"Martin-Olalla JM. Age and sex disaggregation of crude excess deaths during the 2020 spring COVID-19 outbreak in Spain. medRxiv. 2020:2020.08.06.20169326. doi:https:\/\/doi.org\/10.1101\/2020.08.06.20169326","DOI":"10.1101\/2020.08.06.20169326"},{"issue":"6","key":"698_CR148","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/S1473-3099(20)30243-7","volume":"20","author":"R Verity","year":"2020","unstructured":"Verity R, Okell LC, Dorigatti I, et al. Estimates of the severity of coronavirus disease 2019: a model-based analysis. Lancet Infect Dis. 2020;20(6):669\u201377. https:\/\/doi.org\/10.1016\/S1473-3099(20)30243-7.","journal-title":"Lancet Infect Dis"},{"key":"698_CR149","unstructured":"Ferguson N, Laydon D, Nedjati-Gilani G, et al. Report 9: Impact of non-pharmaceutical interventions (NPIs) to reduce COVID-19 mortality and healthcare demand. 2020."},{"issue":"7","key":"698_CR150","doi-asserted-by":"publisher","first-page":"e1003189","DOI":"10.1371\/journal.pmed.1003189","volume":"17","author":"A Hauser","year":"2020","unstructured":"Hauser A, Counotte MJ, Margossian CC, et al. Estimation of SARS-CoV-2 mortality during the early stages of an epidemic: a modeling study in Hubei, China, and six regions in Europe. PLOS Medicine. 2020;17(7):e1003189. https:\/\/doi.org\/10.1371\/journal.pmed.1003189.","journal-title":"PLOS Medicine"},{"key":"698_CR151","doi-asserted-by":"crossref","unstructured":"Meyerowitz-Katz G, Merone L. A systematic review and meta-analysis of published research data on COVID-19 infection-fatality rates. 2020.","DOI":"10.1101\/2020.05.03.20089854"},{"key":"698_CR152","doi-asserted-by":"crossref","unstructured":"Ioannidis J. Infection fatality rate of COVID-19 inferred from seroprevalence data. Bull World Health Organ. 2020.\u00a0https:\/\/www.who.int\/bulletin\/online_first\/BLT.20.265892.pdf","DOI":"10.1101\/2020.05.13.20101253"},{"key":"698_CR153","doi-asserted-by":"crossref","unstructured":"Ward H, Cooke G, Atchison C. Declining prevalence of antibody positivity to SARS-CoV-2: a community study of 365,000 adults. 2020","DOI":"10.1101\/2020.10.26.20219725"},{"key":"698_CR154","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2026116","author":"DF Gudbjartsson","year":"2020","unstructured":"Gudbjartsson DF, Norddahl GL, Melsted P, et al. Humoral immune response to SARS-CoV-2 in Iceland. N Engl J Med. 2020. https:\/\/doi.org\/10.1056\/NEJMoa2026116.","journal-title":"N Engl J Med"},{"key":"698_CR155","doi-asserted-by":"publisher","unstructured":"Brazeau N, Verity R, Jenks S, et al. COVID-19 infection fatality ratio: estimates from seroprevalence. 2020. doi:https:\/\/doi.org\/10.25561\/83545.","DOI":"10.25561\/83545"},{"issue":"2","key":"698_CR156","doi-asserted-by":"publisher","first-page":"154","DOI":"10.3947\/ic.2020.52.2.154","volume":"52","author":"S-J Kang","year":"2020","unstructured":"Kang S-J, Jung SI. Age-related morbidity and mortality among patients with COVID-19. Infect Chemother. 2020;52(2):154\u201364.","journal-title":"Infect Chemother"},{"key":"698_CR157","doi-asserted-by":"publisher","unstructured":"Mak JKL, Kuja-Halkola R, Wang Y, Hagg S, Jylhava J. Frailty and comorbidity in predicting community COVID-19 mortality in the UK Biobank: the effect of sampling. medRxiv. 2020:2020.10.22.20217489. doi:https:\/\/doi.org\/10.1101\/2020.10.22.20217489","DOI":"10.1101\/2020.10.22.20217489"},{"key":"698_CR158","doi-asserted-by":"crossref","unstructured":"Demombynes G. COVID-19 age-mortality curves are flatter in developing countries: the World Bank. 2020.\u00a0World Bank Policy Research Working Paper 9313. https:\/\/openknowledge.worldbank.org\/handle\/10986\/34028","DOI":"10.1596\/1813-9450-9313"},{"key":"698_CR159","doi-asserted-by":"publisher","unstructured":"Lexmond AS, Nouwen CJA, Fourtassi O, Callan JP. Evolution of COVID-19 cases in selected low- and middle-income countries: have they peaked due to high levels of infection and immunity? medRxiv. 2020:2020.09.26.20201814. doi:https:\/\/doi.org\/10.1101\/2020.09.26.20201814","DOI":"10.1101\/2020.09.26.20201814"},{"key":"698_CR160","doi-asserted-by":"publisher","unstructured":"Buss LF, Prete CA, Abrahim CMM, et al. COVID-19 herd immunity in the Brazilian Amazon. medRxiv. 2020:2020.09.16.20194787. doi:https:\/\/doi.org\/10.1101\/2020.09.16.20194787","DOI":"10.1101\/2020.09.16.20194787"},{"key":"698_CR161","doi-asserted-by":"publisher","unstructured":"Prowse TAA, Purcell T, Ba\u00eda-da-Silva DC, et al. Inferred resolution through herd immmunity of first COVID-19 wave in Manaus, Brazilian Amazon. medRxiv. 2020:2020.09.25.20201939. doi:https:\/\/doi.org\/10.1101\/2020.09.25.20201939","DOI":"10.1101\/2020.09.25.20201939"},{"key":"698_CR162","unstructured":"Brazil Ministry of Health. COVID-19 no Brasil, obitos acumulados\u2212\u2212Manaus. 2020."},{"key":"698_CR163","doi-asserted-by":"publisher","unstructured":"Herzog S, Bie JD, Abrams S, et al. Seroprevalence of IgG antibodies against SARS coronavirus 2 in Belgium: a prospective cross-sectional study of residual samples. medRxiv. 2020. https:\/\/doi.org\/10.1101\/2020.06.08.20125179","DOI":"10.1101\/2020.06.08.20125179"},{"key":"698_CR164","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(20)31483-5","author":"M Poll\u00e1n","year":"2020","unstructured":"Poll\u00e1n M, P\u00e9rez-G\u00f3mez B, Pastor-Barriuso R, et al. Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study. Lancet. 2020. https:\/\/doi.org\/10.1016\/s0140-6736(20)31483-5.","journal-title":"Lancet"},{"issue":"10247","key":"698_CR165","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/s0140-6736(20)31304-0","volume":"396","author":"S Stringhini","year":"2020","unstructured":"Stringhini S, Wisniak A, Piumatti G, et al. Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study. Lancet. 2020;396(10247):313\u20139. https:\/\/doi.org\/10.1016\/s0140-6736(20)31304-0.","journal-title":"Lancet"}],"container-title":["European Journal of Epidemiology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10654-020-00698-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10654-020-00698-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10654-020-00698-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,25]],"date-time":"2020-12-25T12:04:04Z","timestamp":1608897844000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10654-020-00698-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":165,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["698"],"URL":"https:\/\/doi.org\/10.1007\/s10654-020-00698-1","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2020.07.23.20160895","asserted-by":"object"}]},"ISSN":["0393-2990","1573-7284"],"issn-type":[{"value":"0393-2990","type":"print"},{"value":"1573-7284","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"5 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 December 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors have no financial interests nor any other conflicts of interest related to this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}